tbuckley/cabot-search huggingface dataset:
Participation of elderly patients with lymphoma and myeloma in clinical trials of novel agents.
Authors: J. Ruan, T. M. Mark, J. Allan, J. Morrison, A. Koirala, P. Martin, M. Coleman, M. Lachs, R. Niesvizky, J. P. Leonard
Journal: Journal of Clinical Oncology (2010)

8091 Background: Improved therapies for elderly patients with lymphoproliferative disorders are needed. Novel agents represent promising options; however, elderly patients are often underrepresented in clinical trials. We report the characteristics and outcomes of geriatric lymphoma and myeloma patients who participated in therapeutic trials at our center. Methods: Using a clinical trial database, we identified all patients over 70 years of age with lymphoma and myeloma who enrolled in trials at Weill Cornell between 1/1/2005 and 6/30/2009. Charts were reviewed for demographics, study completion, and morbidity and mortality including hospitalization and death on study. Study completion with novel agents was defined as treatment until at least the first scheduled response assessment. Outcomes were analyzed using the non-parametric Kruskal-Wallis method. Results: Of 170 patients identified, 157 had available clinical information. At study entry, median age was 75 y (range 70-87), with 20% over 80 y. The M:F ratio was 1.7:1; 78% had ECOG PS of 0-1; 90% were Caucasians; and 64% were married. Eighty-seven pts had non-Hodgkin lymphoma (51% indolent, 49% aggressive subtypes). Thirty-eight NHL pts received chemo-based regimens, 49 received novel agents including mAbs, proteasome inhibitors, and IMiDs. Seventy pts had multiple myeloma (MM), 54% with ISS stage 2 and 26% stage 3. Sixty-one MM pts received novel agents. Sixty-four percent of NHL pts and 87% of MM pts completed the studies. The main reasons for study discontinuation were toxicity (33%) and disease progression (67%). Overall mortality on study was 10%; 36% required hospitalization. In NHL pts, aggressive histologies and chemo-based regimens were associated with increased hospitalizations (p=0.014 and p=0.033, respectively). Aggressive histologies trended with increased mortality (p=0.062), while novel agents trended with disease progression (p=0.076). Conclusions: Novel therapeutic agents can be safely administered to elderly patients with lymphoma and myeloma on clinical trials. Most patients can reach study completion in our experience. Advanced age in itself should not be an exclusion factor for clinical trial participation. No significant financial relationships to disclose.
A Randomized Trial Comparing Bangerter Filters and Patching for the Treatment of Moderate Amblyopia in Children
Authors: Robert P Rutstein, Graham E Quinn, Elizabeth L Lazar, Roy W Beck, Dean J Bonsall, Susan A Cotter, Eric R Crouch, Jonathan M Holmes, Darren L Hoover, David A Leske, Ingryd J Lorenzana, Michael X Repka, Donny W Suh
Journal: Ophthalmology (2010)
Abstract 18940: Efficacy and Safety of Tirofiban for Bridging Therapy in Patients at High-Risk for Stent Thrombosis Undergoing Surgery
Authors: Desai Wu, Stanley Chou, Amanda Lamer, Hai Tran, Sanjay Kaul
Journal: Circulation (2010)

Background: Patients with drug-eluting stent (DES) who need urgent surgery are at increased risk of surgical bleeding while on clopidogrel. However, preoperative clopidogrel discontinuation is asso...
Abstract 14585: Prognostic Significance of Left Ventricular Diastolic Function Associated with Inflammatory Response and Survival in Burn Patients
Authors: Jen-kuang Lee, Cho-Kai Wu, Chih-Yun Lin, Chia-Ti Tsai, Futien Chiang
Journal: Circulation (2011)

Purpose: Severe inflammation leads to cardiac diastolic dysfunction, an independent prognostic marker for mortality of critically ill patients. We investigated a possible molecular mechanism by whi...
Abstract 12196: Self-reported Adherence to a Low Sodium Diet Independently Predicts Cardiac Event-free Survival in Patients with Heart Failure
Authors: Eun Kyeung Song, Debra K Moser, Seok-Min Kang, Terry A Lennie
Journal: Circulation (2012)

Background. A low sodium diet (LSD) is a standard component of self-care for better health outcomes in heart failure (HF) patients. Clinicians rely on patients’ self-report of following an LSD to d...
The asthma-COPD overlap syndrome: Transcription factors GATA3 and STAT6 as possible markers
Authors: Lada Sorokina, Valeriy Mineev, Michail Nyoma, Valeria Lim, Anna Eremeeva, Vasiliy Ivanov, Vasiliy Trofimov
Journal: European Respiratory Journal (2014)

The aim of the study is to analyze an expression of transcription factors (GATA3, STAT6, et al.) and IFN-γ in peripheral blood of patients with asthma-COPD overlap syndrome and asthma.  Materials and methods. 24 patients with asthma and 18 with asthma-COPD overlap syndrome were examined. The expression of protein level of GATA3 and STAT6 were analyzed by Western blotting and mRNA of IFN-γ - by RT-PCR (primers have been developed on the basis of known sequences (GenBank)). Expression levels of mRNA and protein were estimated concerning level of β-actin. Preparation of cell lysates, and the Western blotting were performed through the standard procedure. mRNA quantity reverse transcription PCR followed by electrophoresis on 1,5% agarose gel was performed. Lymphocytes derived from patientswere additionally analyzed after 1h incubation using IMDM with and without IL-4 (in the concentration 10 ng/ml). The spirometry with bronchodilation test and blood and sputum analyses were performed in all examined patients.  Results. GATA3 levels were significantly decreased in patients with asthma-COPD overlap syndrome in comparison with asthma (p=0,014) (U-criterion). GATA3 and STAT6 levels were significantly decreased also after the IL-4 action in patients with asthma-COPD overlap syndrome in comparison with asthma (p=0,001 and p=0,008) (U-criterion). On the contrary significant increase of mRNA IFN-γ was registered in lymphocytes derived from patients with asthma-COPD overlap syndrome (p=0,015) (U-criterion).  Conclusion: Transcription factors GATA3 and STAT6 play the important role in the pathogenesis of asthma and may be used as markers in differentiation from patients with asthma-COPD overlap syndrome.
The Meaning of Psychosomatic Medicine
Authors: Carl Binger, George Draper
Journal: New England Journal of Medicine (1947)

notion that the mind and body are closely related in their behavior is as old as medicine and philosophy. Aristotle and Hippocrates knew it; Paracelsus proclaimed it; and Jean Paul Marat elaborated upon it he whose career as a distinguished ophthalmologist ended before he took his tragic part in the French Revolution. But for the more modern origins of what is now called psychosomatic medicine we must look to the Germany of the early eighteen hundreds particularly to the work of Nasse (1778-1851) and Jacobi (1775-1858). In America, Oliver Wendell Holmes, Sr., was alive to the effects of social and personal problems on health, but he judged his professional colleagues not yet ready to accept such ideas, so he dispensed them in the form of his three medicated novels Elsie Venner, A Mortal Antipathy and The Guardian AngeL Toward the close of the last century a Boston physician, Dr. Robert T. Edes, wrote The New England Invalid, a classical description of a familiar type of woman patient in whom emotional disturbances and physical symptoms co-exist. A few years later Dr. James Jackson Putnam, the first professor of Neurology at Harvard, and one of the earliest Americans to come under the influence of Freud, wrote an article called Not the Disease Only But Also the Man. These random historical items are straws pointing the wind. Many others could be found. In our own time and place it is Dr.
Standard definition of child overweight and obesity worldwide
Authors: Y. Wang
Journal: BMJ (2000)

Editor—Different standards have been proposed to define overweight and obesity in childhood, and as a result it is difficult to compare published results. An international standard is useful for making international comparisons and monitoring the global epidemic of obesity. The new standard proposed by Cole et al (the International Obesity Task Force standard) meets this demand.1 By contrast, the World Health Organization recommended using the sex-age specific body mass index 85th centiles derived from data from the United States' first national health and nutrition examination survey collected in 1971-4 to define adolescent overweight for international use.2,3

Using data from large nationwide surveys from China (1991 China health and nutrition survey), Russia (1992 Russian longitudinal monitoring survey), and the United States (third national health and nutrition examination survey, 1988-94), we compared Cole et al's and the World Health Organization standards to assess overweight in children (aged 6-9) and adolescents (10-18). These three countries' total populations account for about a quarter of the global population.

We examined the prevalence of overweight in each country by using each standard. The table shows that the two standards produced consistent estimates of the prevalence of overweight, although that proposed by Cole et al (the IOTF standard) produced a slightly lower estimate in children than did the WHO standard but a slightly higher estimate in adolescents. In general, the agreement was better in all adolescents, girls aged 6-9, and male adolescents. We calculated the κ coefficient to examine the agreement at an individual level. κ⩾0.8 suggests an excellent agreement.4 κ values also suggested an excellent agreement between these two standards, although the agreement varied by sample, age group, and sex. 

Results from studies in older children and adolescents using these two standards would seem to be comparable, although the standard proposed by Cole et al is better for international use. We found, however, that the prevalence of overweight is much lower in adolescents than children in the samples from the surveys in China and Russia, but the prevalence was similar in American children and adolescents.

Further research is needed to understand whether our findings are mainly due to socioeconomic and behavioural factors; alternatively, both standards may have a higher sensitivity for indentifying individuals as overweight among children than adolescents in developing countries, where children and adolescents' growth, development, and maturation patterns are different from those of the reference populations.
St Jerome Reading
Authors: M. Therese Southgate
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Haplotype HLA-B8-DR3 Confers Susceptibility to Hepatitis C Virus-Related Mixed Cryoglobulinemia
Authors: Marco Lenzi, Magda Frisoni, Vilma Mantovani, Paolo Ricci, Luigi Muratori, Raffaella Francesconi, Mariaclara Cuccia, Silvio Ferri, Francesco B. Bianchi
Journal: Blood (1998)
Abstract 19127: Gamma glutamyltransferase and Risk of Incident Heart Failure
Authors: Setor K Kunutsor, Jussi Kauhanen, Javed Butler, Jari A Laukkanen, Hassan Khan
Journal: Circulation (2014)

Background:  The relationship between gamma glutamyltransferase (GGT) and incident heart failure (HF) has not been reliably quantified.   Methods and Results:  We assessed the association between GGT and HF risk in a population-based cohort of 1,797 men aged 42-61 years free from HF at baseline. Additionally, we performed a meta-analysis of relevant prospective studies identified from MEDLINE, EMABSE, and Web of Science databases. During a mean follow-up of 20.4 years, 155 participants developed HF (4.2 cases per 1000 person-years). Log e  GGT levels was approximately log-linearly associated with HF risk. The age adjusted hazard ratio (HR) for HF per 1 standard deviation (SD) higher baseline GGT levels was 1.66 (95% confidence interval [CI] 1.43-1.94). This association persisted after adjusting for established HF risk factors 1.48 (95% CI:1.24, 1.76).These findings remained consistent in analyses accounting for incident coronary heart disease events, excluding individuals with prior cardiovascular events, and in subgroups defined by several individual participant characteristics. In pooled random effects meta-analysis of five population-based studies (210,858 participants and 1,754 HF events), the HR for HF per 1 SD higher baseline GGT level was 1.30 (95% CI: 1.23-1.38) with no evidence of heterogeneity between contributing studies.   Conclusions:  There is a positive log-linear association between GGT and risk of incident HF, which is independent of established risk factors. Further research is needed to assess any causal relevance to the association.   Figure 1  Cumulative hazard curves for incident heart failure by quartiles of GGT  The median GGT level (IU/L) was 12.0 (range 8-13) for the lowest quartile; 17.0 (range 15-19) for the second quartile; 24.5 (range 21-27) for the third quartile; and 43.0 (range 31-56) for the top quartile   Figure 2  Hazard ratios for heart failure by quartiles of baseline GGT levels  Hazard ratios (HR) were calculated in reference to the first quartile of GGT, and plotted against the geometric mean GGT within each category. 95% CIs were calculated from floating variances (including the reference group).
Characterization of a Hedgehog pathway antagonist in a mouse medulloblastoma allograft model.
Authors: Hua Tian, Derek Marshall, Christina Ahn, Zora Modrusan, Leslie Lee, Lesley Murray, Stephen Gould, Oivin Guicherit, Changgeng Qian, Hui Qu, Guang-Xin Xu, Hank Dudek, Karen Kotkow, Lee Rubin, Frederic De Sauvage
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

5639 

Constitutive activation of the Hedgehog pathway accounts for 25% of sporadic medulloblastoma, the most common childhood brain cancer. It has been demonstrated previously that treatment of a medulloblastoma mouse model (Ptch1 P53−/−) with a Hh pathway antagonist, leads to complete eradication of tumors. In order to further characterize the mechanism of action of Cur-691, we have established an allograft model derived from Ptch1 p53 mice and observed total regression of established subcutaneous medulloblastoma allografts following 28 days treatment with Cur-691. Importantly, this effect was found to be durable as no tumor regrowth was noted during 60-day following cessation of treatment. In the current study, we characterized pharmacokinetic pharmacodynamic (PK/PD) profile of Cur-691 within the tumor, evaluated changes in apoptosis and cell proliferation, and performed gene expression microarray analysis to identify the molecular pathways altered by Cur-691 treatment. PK/PD analysis demonstrated that concentrations of Cur-691 found in the tumor correlated with repression of the Hh pathway with trough values of less than 1mM. Immuno-fluorescence analysis detected a rapid and progressive increase in cell death and inhibition of cell proliferation confined within the tumor component of the allograft following Cur-691 treatment, indicating that the drug specifically targets Ptch1 tumor cells, while leaving the stromal and vasculature components of the allograft intact. In addition to down-regulation of several well-characterized Hh target genes, we also observed profound changes in cell cycle regulation and DNA replication following Cur-691 treatment by microarrays. Many signature genes upregulated in desmoplastic (Hh driven) medulloblastoma are immediately modulated by Cur-691 treatment, further confirming that transcription of these signature genes are driven by Hh signaling. Together these data support targeting the Shh pathway for the treatment of desmoplastic medulloblastoma or other cancer where activation of the Hh pathway has been implicated.
Current Clinical Practice.
Authors: Franz H. Messerli
Journal: Annals of Internal Medicine (1987)

Focuses on the therapeutic management of medical disorders as practiced by 13 of the leading private clinics in the U.S.--Cleveland, Geisinger, Guthrie, Henry Ford, Joslin, Lahey, Lovelace-Bataan, Marshfield, Mayo, Ochsner, Palo Alto, Scripps, and Scott & White. Provides clear, practical guidelines on how specific disorders are managed. Emphasizes outpatient management and treatment of adults. Presents concise and detailed aspects of drug and non-drug treatment, allowing the reader to select the therapeutic regimen most appropriate for a specific situations. Shows how high-standard medicine is practiced on a day-to-day and cost-effective basis.
Abstract 16647: PKC Inhibition Using a Nonpolymeric Drug-Eluting Stent Platform Does Not Affect Neointimal Hyperplasia in a Porcine Coronary Model
Authors: Oana Sorop, Heleen M van Beusekom, Richard van Duin, Rorry van Haeren, Ilona Krabbendam, Willem J van der Giessen
Journal: Circulation (2010)
Abstract P3-04-02: Multiple subtypes of triple negative breast cancer are dependent on androgen receptor
Authors: Valerie N Barton, Nicholas C D'Amato, Michael A Gordon, Britta M Jacobsen, Jennifer K Richer
Journal: Cancer Research (2015)

Abstract Triple negative breast cancer (TNBC) constitutes 10-20% of invasive breast carcinomas and has the lowest five-year survival rate. Currently, there are no targeted therapies for TNBC. Recent studies demonstrate that the androgen receptor (AR) is expressed in up to a third of TNBC. AR is highly expressed in the "luminal AR (LAR)" molecular TNBC subtype, but is also present in other TNBC subtypes and may present an opportunity for targeted therapy. We hypothesized that AR+ TNBC critically depend on AR and that AR inhibition will decrease tumor burden in preclinical models of breast cancer. To determine the extent to which AR+ TNBC depend on AR, we inhibited AR activity with the AR antagonist enzalutamide (ENZ) and shRNAs against AR in multiple TNBC subtypes. Treatment with ENZ prevented AR nuclear localization in response to DHT in multiple TNBC cell lines, reduced baseline proliferation in 2D culture (p&amp;lt;0.05), and decreased anchorage independent growth in soft agar (p&amp;lt;0.01). AR knockdown significantly reduced proliferation (p&amp;lt;0.001) and increased apoptosis (p&amp;lt;0.001) compared to cells transduced with a non-targeting control. In addition to reduced proliferation, AR knockdown or treatment with ENZ altered cellular morphology from stellate to round in Matrigel and significantly decreased migration (p&amp;lt;0.05) and invasion (p&amp;lt;0.001) of cell lines spanning multiple TNBC subtypes. Microarray profiling and ELISA of TNBC lines treated with DHT and ENZ suggested that AR regulation of the EGFR ligand amphiregulin (AREG, p&amp;lt;0.05) is a mechanism by which AR influences proliferation, migration and invasion in TNBC. Indeed, treatment with exogenous AREG rescued decreased proliferation, migration and invasion of AR knockdown cell lines (p&amp;lt;0.05). In vivo, ENZ significantly decreased tumor viability (p=0.008) and increased necrosis (p=0.009) in SUM159PT xenografts. Our findings suggest that AR influences both proliferation and invasion of AR+ TNBC cells representing multiple TNBC subtypes and provide promising preclinical data on the efficacy of ENZ in AR+ TNBC. Thus, inhibition of AR by anti-androgens such as ENZ may represent an effective targeted therapy for TNBC. Citation Format: Valerie N Barton, Nicholas C D'Amato, Michael A Gordon, Britta M Jacobsen, Jennifer K Richer. Multiple subtypes of triple negative breast cancer are dependent on androgen receptor [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-04-02.
Abstract 2835: Non-Cardiac Findings on Cardiovascular Magnetic Resonance Imaging Are Common: Impact of Imaging Sequences and Reading Session Format
Authors: Benjamin P Romney, Faisal Khosa, Daniel N Costa, Peter Chan, Neil M Rofsky, Warren J Manning
Journal: Circulation (2008)

Purpose The true prevalence of non-cardiac pathology on clinical cardiovascular magnetic resonance (CMR) imaging is not fully defined. While prior studies have shown few non-cardiac findings (NCFs) on CMR reports, this may be an underestimate. We sought to determine the prevalence of NCFs by using a second imaging review with specific attention to NCFs. Materials and Methods The images from all 495 clinical CMR studies performed at our center in 2006 were independently reviewed by a radiologist for the presence of NCFs, defined as benign (e.g., pleural effusion, hiatal hernia), indeterminate (e.g. pleural effusion, enlarged lymph node), or worrisome (e.g. lung nodule, aortic dissection). Data were compared with NCFs listed in the subject’s clinical CMR report, which also included information as to whether a radiologist was physically present at the original reading session. Results The initial clinical CMR reports included 105 NCFs (30 benign, 68 indeterminate, and 7 worrisome). On focused image review, 295 NCFs (144 [49%] benign, 137 [46%] indeterminate, 14 [5%] worrisome) were identified in 212/495 (43%) studies, with 113 studies (23%) containing indeterminate and/or worrisome NCFs. The vast majority (281/295, 95%) of NCFs were visible on either the initial scout images (186/295, 63%) or thoracic T1w axial fast spin echo images (176/295, 60%). Overall, 36% (105/295) of NCFs (21% of benign, 50% of indeterminate, and 50% of worrisome) detected on our image review were included in the original clinical CMR report. NCFs were reported more frequently when a radiologist was present for the joint CMR readout (42% 95/228;vs. 15% 10/67;, p=0.003). Conclusion Indeterminate or worrisome NCFs are more common than previously reported, and involve nearly a quarter of clinical CMR studies. The vast majority of NCFs were visible on scout and T1w axial images. A joint reading session with cardiologists and radiologists improves the detection and reporting of NCFs. These data also highlight the importance of training CMR practitioners to identify NCFs.
Stem Cell Transplantation for Secondary Acute Myeloid Leukemia: Evaluation of Transplantation as Initial Therapy or Following Induction Chemotherapy
Authors: Jeanne E. Anderson, Ted A. Gooley, Gary Schoch, Claudio Anasetti, William I. Bensinger, Reginald A. Clift, John A. Hansen, Jean E. Sanders, Rainer Storb, Frederick R. Appelbaum
Journal: Blood (1997)
Who keeps the first outpatient appointment?
Authors: P J Carpenter, G R Morrow, A C Del Gaudio, B A Ritzler
Journal: American Journal of Psychiatry (1981)

The authors studied 1,106 consecutive patients who called for an initial outpatient appointment at a medical center department of psychiatry during a one-year period. The 759 (68.6%) patients who kept their initial scheduled appointment differed from the 347 (31.4%) who did not in age, previous psychiatric treatment, source of referral, chief complaint, and number of days they waited for an appointment. A telephone follow-up conducted with almost 30% of those who did not keep their initial appointment revealed that of those contacted, 26 (25%) sought other routes for psychiatric help and 23 (22%) made a subsequent contact at the facility studied.